Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 22, 2003. The document consists of multiple Schedule 5 Blocklisting Six Monthly Returns submitted to the UK Listing Authority. These schedules detail the status of various employee share option schemes for the period from December 28, 2002, to June 27, 2003.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on equity capitalization and share option scheme administration.
- Total Shares in Issue: 5,983,313,926 (as of the end of the period).
- Share Option Activity: The filing details shares issued, allotted, and remaining under 13 distinct share option schemes.
Material Changes and Share Scheme Activity
The filing reports the following activity across various share option schemes during the six-month period:
- Glaxo Wellcome International Share Option Scheme: 751,599 shares issued; 22,504,679 shares remain unissued.
- Glaxo Group Limited Share Option Scheme: 662,432 shares issued; 3,814,277 shares remain unissued.
- SmithKline Beecham 1989 Executive Share Option Plan (Unapproved - ADS): 707,824 shares issued; 1,684,450 shares remain unissued.
- SmithKline Beecham 1989 Executive Share Option Plan (Approved - Ordinary Shares): 351,401 shares issued; 730,266 shares remain unissued.
- Burroughs Wellcome Management Stock Option Plan: 16,523 shares issued; 0 shares remain unissued (scheme fully utilized).
- Other Schemes: Various smaller issuances occurred in the Glaxo Wellcome UK schemes, SmithKline Beecham Unapproved Ordinary Shares, and Wellcome Executive schemes. No shares were issued under the Glaxo Wellcome 1999 Plan or Wellcome 500 Plan during this period.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory compliance document regarding share blocklisting.
Investor Verification Checklist
- Verify the total number of shares in issue (5,983,313,926) against the company's latest annual report or Form 20-F.
- Confirm the dilution impact of the 2,686,248 total shares issued across all schemes during this six-month period.
- Review the specific terms and vesting schedules of the "Burroughs Wellcome Management Stock Option Plan," which reached a zero balance of unissued shares.
- Check subsequent filings for updates on the large block of unissued shares (over 22 million) in the Glaxo Wellcome International Share Option Scheme.